Shopping Cart

Chronic Lymphocytic Leukemia CLL Global Clinical Trials Review, H1, 2016

SKU
GDHC3477CTIDB
READ MORE
USD 2,500
Single User License
USD 2,500
Site License
USD 5,000
Corporate User License
USD 7,500

Chronic Lymphocytic Leukemia (CLL) Global Clinical Trials Review, H1, 2016

Summary

GlobalData's clinical trial report, "Chronic Lymphocytic Leukemia (CLL) Global Clinical Trials Review, H1, 2016" provides an overview of Chronic Lym

READ MORE
  • Details
  • Table Of Content
  • Licence Rights
  • Section Purchase
  • Products and Companies

Chronic Lymphocytic Leukemia (CLL) Global Clinical Trials Review, H1, 2016

Summary

GlobalData's clinical trial report, "Chronic Lymphocytic Leukemia (CLL) Global Clinical Trials Review, H1, 2016" provides an overview of Chronic Lymphocytic Leukemia (CLL) clinical trials scenario. This report provides top line data relating to the clinical trials on Chronic Lymphocytic Leukemia (CLL). Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary database-Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

The report provides a snapshot of the global clinical trials landscape

Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status

The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company

The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment

The Report provides enrollment trends for the past five years

Report provides latest news for the past three months

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Reasons To Buy

Assists in formulating key business strategies with regards to investment

Helps in identifying prominent locations for conducting clinical trials which saves time and cost

Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities

Supports understanding of trials count and enrollment trends by country in global therapeutics market

Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials

Facilitates clinical trial assessment of the indication on a global, regional and country level

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

READ MORE

Scope

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 5

Report Guidance 6

Clinical Trials by Region 7

Clinical Trials and Average Enrollment by Country 8

Top Five Countries Contributing to Clinical Trials in Asia-Pacific 10

Top Five Countries Contributing to Clinical Trials in Europe 11

Top Countries Contributing to Clinical Trials in North America 12

Top Five Countries Contributing to Clinical Trials in Middle East and Africa 13

Top Five Countries Contributing to Clinical Trials in Central and South America 14

Clinical Trials by G7 Countries: Proportion of Chronic Lymphocytic Leukemia (CLL) to Oncology Clinical Trials 15

Clinical Trials by Phase in G7 Countries 16

Clinical Trials in G7 Countries by Trial Status 17

Clinical Trials by E7 Countries: Proportion of Chronic Lymphocytic Leukemia (CLL) to Oncology Clinical Trials 18

Clinical Trials by Phase in E7 Countries 19

Clinical Trials in E7 Countries by Trial Status 20

Clinical Trials by Phase 21

In Progress Trials by Phase 22

Clinical Trials by Trial Status 23

Clinical Trials by End Point Status 24

Subjects Recruited Over a Period of Time 25

Clinical Trials by Sponsor Type 26

Prominent Sponsors 27

Top Companies Participating in Chronic Lymphocytic Leukemia (CLL) Therapeutics Clinical Trials 28

Prominent Drugs 29

Latest Clinical Trials News on Chronic Lymphocytic Leukemia (CLL) 30

Jun 09, 2016: AbbVie Reinforces Commitment to Hematologic Oncology at 21st European Hematology Association Annual Congress Including 10 Abstracts on Investigational Medicine Venetoclax 30

Jun 06, 2016: AbbVie Builds Upon Robust Body of IMBRUVICA (ibrutinib) Data with Phase 3 Longer-Term Studies in Patients with Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma Presented at the American Society of Clinical Oncology Annual Meeting 30

Jun 06, 2016: TG Therapeutics Announces Long-Term Follow-up of TGR-1202 Demonstrates a Differentiated Safety Profile and High Response Rates in CLL and NHL in Data Presented at the 52nd Annual Meeting of the American Society of Clinical Oncology 32

May 24, 2016: REDX PHARMA: Proof of concept with key oncology lead 33

May 20, 2016: TG Therapeutics Announces Clinical Data Presentations at the Upcoming 21st European Hematology Association Annual Congress 33

May 19, 2016: Ofatumumab Data to Be Presented at 21st Congress of EHA 33

May 18, 2016: Juno Therapeutics to Highlights New Efficacy, Safety, and Durability data for JCAR-014 at the 2016 American Society of Clinical Oncology Annual Meeting 34

May 18, 2016: AbbVie To Present Data on IMBRUVICA (ibrutinib) at ASCO 2016 34

May 18, 2016: Juno Therapeutics to Highlight JCAR-015 at the 2016 American Society of Clinical Oncology Annual Meeting 35

May 18, 2016: TG Therapeutics Announces Clinical Data Presentation at the Upcoming 52nd Annual Meeting of the American Society of Clinical Oncology 35

May 16, 2016: AbbVie announces The Lancet Oncology publication of Phase 2 data showing high overall response rates for Venetoclax in patients with relapsed/refractory chronic lymphocytic leukaemia with 17p deletion 36

May 09, 2016: U.S. FDA Expands IMBRUVICA (ibrutinib) Label to Include Overall Survival Data in Previously Untreated Chronic Lymphocytic Leukemia and New Indication for Small Lymphocytic Lymphoma Patients 37

Apr 20, 2016: Acetylon Announces the Presentation of Preclinical Data at AACR Supporting the Use of Selective HDAC6 Inhibition to Modulate Chronic Lymphocytic Leukemia (CLL) Immunobiology 38

Apr 19, 2016: MacroGenics Presents Data from ROR1 x CD3 DART Preclinical Program at AACR Annual Meeting 2016 38

Apr 18, 2016: Immunomedics Announces Potent Anti-Tumor Activities with IMMU-114 in Preclinical Study in Acute and Chronic Leukemia 39

Clinical Trial Profile Snapshots 40

Appendix 1164

Abbreviations 1164

Definitions 1164

Research Methodology 1165

Secondary Research 1165

About GlobalData 1166

Contact Us 1166

Disclaimer 1166

Source 1167


List Of Figure

List of Figures

Chronic Lymphocytic Leukemia (CLL) Therapeutics, Global, Clinical Trials by Region (%), 2016* 7

Chronic Lymphocytic Leukemia (CLL) Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2016* 8

Chronic Lymphocytic Leukemia (CLL) Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2016* 9

Chronic Lymphocytic Leukemia (CLL) Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2016* 10

Chronic Lymphocytic Leukemia (CLL) Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2016* 11

Chronic Lymphocytic Leukemia (CLL) Therapeutics Clinical Trials, North America, Top Countries (%), 2016* 12

Chronic Lymphocytic Leukemia (CLL) Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries (%), 2016* 13

Chronic Lymphocytic Leukemia (CLL) Therapeutics Clinical Trials, Central and South America, Top Five Countries (%), 2016* 14

Proportion of Chronic Lymphocytic Leukemia (CLL) to Oncology Clinical Trials, G7 Countries (%), 2016* 15

Chronic Lymphocytic Leukemia (CLL) Therapeutics, G7 Countries, Clinical Trials by Phase, 2016* 16

Chronic Lymphocytic Leukemia (CLL) Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2016* 17

Proportion of Chronic Lymphocytic Leukemia (CLL) to Oncology Clinical Trials, E7 Countries (%), 2016* 18

Chronic Lymphocytic Leukemia (CLL) Therapeutics, E7 Countries, Clinical Trials by Phase, 2016* 19

Chronic Lymphocytic Leukemia (CLL) Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2016* 20

Chronic Lymphocytic Leukemia (CLL) Therapeutics, Global, Clinical Trials by Phase (%), 2016* 21

Chronic Lymphocytic Leukemia (CLL) Therapeutics, Global, Clinical Trials In Progress by Phase, 2016* 22

Chronic Lymphocytic Leukemia (CLL) Therapeutics, Global, Clinical Trials by Trial Status, 2016* 23

Chronic Lymphocytic Leukemia (CLL) Therapeutics Clinical Trials, Global, by End Point Status, 2016* 24

Chronic Lymphocytic Leukemia (CLL) Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2011-2015 25

Chronic Lymphocytic Leukemia (CLL) Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2016* 26

Chronic Lymphocytic Leukemia (CLL) Therapeutics Clinical Trials, Global, Key Sponsors, 2016* 27

Chronic Lymphocytic Leukemia (CLL) Therapeutics Clinical Trials, Global, Top Companies by Phase, 2016* 28

Chronic Lymphocytic Leukemia (CLL) Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2016* 29

GlobalData Methodology 1165


List Of Table

List of Tables

Chronic Lymphocytic Leukemia (CLL) Therapeutics, Global, Clinical Trials by Region, 2016* 7

Chronic Lymphocytic Leukemia (CLL) Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2016* 8

Chronic Lymphocytic Leukemia (CLL) Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2016* 9

Chronic Lymphocytic Leukemia (CLL) Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2016* 10

Chronic Lymphocytic Leukemia (CLL) Therapeutics Clinical Trials, Europe, Top Five Countries, 2016* 11

Chronic Lymphocytic Leukemia (CLL) Therapeutics Clinical Trials, North America, Top Countries, 2016* 12

Chronic Lymphocytic Leukemia (CLL) Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries, 2016* 13

Chronic Lymphocytic Leukemia (CLL) Therapeutics Clinical Trials, Central and South America, Top Five Countries, 2016* 14

Proportion of Chronic Lymphocytic Leukemia (CLL) to Oncology Clinical Trials, G7 Countries (%), 2016* 15

Chronic Lymphocytic Leukemia (CLL) Therapeutics, G7 Countries, Clinical Trials by Phase, 2016* 16

Chronic Lymphocytic Leukemia (CLL) Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2016* 17

Proportion of Chronic Lymphocytic Leukemia (CLL) to Oncology Clinical Trials, E7 Countries (%), 2016* 18

Chronic Lymphocytic Leukemia (CLL) Therapeutics, E7 Countries, Clinical Trials by Phase, 2016* 19

Chronic Lymphocytic Leukemia (CLL) Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2016* 20

Chronic Lymphocytic Leukemia (CLL) Therapeutics, Global, Clinical Trials by Phase, 2016* 21

Chronic Lymphocytic Leukemia (CLL) Therapeutics, Global, Clinical Trials In Progress by Phase 2016* 22

Chronic Lymphocytic Leukemia (CLL) Therapeutics, Global, Clinical Trials by Trial Status, 2016* 23

Chronic Lymphocytic Leukemia (CLL) Therapeutics Clinical Trials, Global, by End Point Status, 2016* 24

Chronic Lymphocytic Leukemia (CLL) Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2011-2015 25

Chronic Lymphocytic Leukemia (CLL) Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2016* 26

Chronic Lymphocytic Leukemia (CLL) Therapeutics Clinical Trials, Global, Key Sponsors, 2016* 27

Chronic Lymphocytic Leukemia (CLL) Therapeutics Clinical Trials, Global, Top Companies by Phase, 2016* 28

Chronic Lymphocytic Leukemia (CLL) Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2016* 29

To know more information on Purchase by Section, please send a mail to

Products

Chronic Lymphocytic Leukemia (CLL) Clinical Trials, Phase, Completed, Ongoing, Planned, End Points, Trial Locations, Trial Designs, Subjects Recruited, Safety, Efficacy, Bioequivalence, Pharmacokinetics, Pharmacodynamic, Sponsor, Collaborator, CRO's, Terminated, Suspended and Withdrawn trials of Chronic Lymphocytic Leukemia (CLL), Pfizer, AstraZeneca, Novartis, GlaxoSmithKline, Sanofi, Eli Lilly and Company, Johnson & Johnson, Merck & Co., Inc, Bristol-Myers Squibb Company, Abbott Laboratories, Hoffmann-La Roche Ltd., Celgene Corporation, Daiichi Sankyo Company, Ltd., Bayer AG, Eisai Inc., GE Healthcare, Biogen Idec Inc., Copharos Inc., Wyeth Pharmaceuticals Inc., National Cancer Center, The University of Texas M. D. Anderson Cancer Center, Vanderbilt Medical Center, Memorial Sloan Kettering Cancer Center, Cancer Research UK, North Central Cancer Group, Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Fred Hutchinson Cancer Research Center, European Organization for Research and Treatment of Cancer, Dana-Farber Cancer Institute, The Cancer and Leukemia Group B, Columbia University, UCLA's Jonsson Comprehensive Cancer Center, Case Comprehensive Cancer Center, Mayo Clinic, Duke University, Ohio State University, University of Pennsylvania.

Companies

F. Hoffmann-La Roche Ltd.

AbbVie Inc.

Celgene Corporation

GlaxoSmithKline Plc

Novartis AG

Johnson & Johnson

Gilead Sciences, Inc.

Sanofi

Bayer AG

AstraZeneca Plc

Brand Description
History Color sit amet, consectetur adipiscing elit. In gravida pellentesque ligula, vel eleifend turpis blandit vel. Nam quis lorem ut mi mattis ullamcorper ac quis dui. Vestibulum et scelerisque ante, eu sodales mi. Nunc tincidunt tempus varius. Integer ante dolor, suscipit non faucibus a, scelerisque vitae sapien.